Avid, a subsidiary of Eli Lilly and Company, focuses on developing molecular imaging compounds that can detect the first stages of diseases like Alzheimer's, Dementia with Lewy Bodies, Parkinson's, and Diabetes Mellitus. Their imaging agents have the potential to revolutionize the clinical course of these conditions by enabling early treatment and management before symptoms develop. Avid's expertise lies in molecular brain imaging, particularly in targeting amyloid plaques for Alzheimer's detection and vesicular monoamine transporter (VMAT-2) for pathology imaging in dementia, Parkinson's, and diabetes research.